Synonyms: BCX-4430 | BCX4430 | Immucillin-A
Compound class:
Synthetic organic
Comment: Galidesivir (BCX4430) is an adenosine analogue and broad-spectrum antiviral agent [3]. It was originally developed as a treatment for hepatitis C infection, but has subsequently demonstrated activity against Ebola, Marburg and Zika [1] viruses, and was most recently evaluated for potential to treat SARS-CoV-2 infection (COVID-19). Mechanistically it inhibits the virus' RNA-dependent RNA-polymerase (RdRp), that acts as a nonobligate RNA chain terminator.
|
|
Classification | |
Compound class | Synthetic organic |
IUPAC Name |
(2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol |
International Nonproprietary Names | |
INN number | INN |
10284 | galidesivir |
Synonyms |
BCX-4430 | BCX4430 | Immucillin-A |
Database Links | |
BindingDB Ligand | 50513995 |
CAS Registry No. | 249503-25-1 (source: WHO INN record) |
ChEMBL Ligand | CHEMBL1236524 |
DrugBank Ligand | DB11676 |
GtoPdb PubChem SID | 461663475 |
PubChem CID | 10445549 |
RCSB PDB Ligand | UA2 |
Search Google for chemical match using the InChIKey | AMFDITJFBUXZQN-KUBHLMPHSA-N |
Search Google for chemicals with the same backbone | AMFDITJFBUXZQN |
Search PubMed clinical trials | galidesivir |
Search PubMed titles | galidesivir |
Search PubMed titles/abstracts | galidesivir |
UniChem Compound Search for chemical match using the InChIKey | AMFDITJFBUXZQN-KUBHLMPHSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | AMFDITJFBUXZQN-KUBHLMPHSA-N |